“Immune Biomarkers of Percutaneous Coronary Intervention Adverse Outcomes in Myocardial Infarction and Stable Angina Patients” (2018) Asian Journal of Pharmaceutics (AJP), 12(03). doi:10.22377/ajp.v12i03.2653.